Efficacy and Safety of BI 10773 in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin
Status: | Archived |
---|---|
Conditions: | Diabetes |
Therapuetic Areas: | Endocrinology |
Healthy: | No |
Age Range: | Any |
Updated: | 7/1/2011 |
Start Date: | September 2010 |
A Randomised, Double-blind, Placebo-controlled Parallel Group Efficacy and Safety Study of BI 10773 (10 and 25 mg Administered Orally Once Daily) Over 24 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control Despite Background Therapy With Pioglitazone Alone or in Combination With Metformin
This study will investigate the efficacy and safety of BI 10773 in type 2 diabetic patients
in order to provide these data for approval for BI 10773 by regulatory authorities as an
antidiabetic agent as add-on therapy to pioglitazone alone or in combination with metformin.
We found this trial at
24
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials